NASDAQ
LENZ Therapeutics, Inc. (LENZ)
♥ 389 Thanks from members
LENZ Therapeutics faces heightened financial volatility and a widening quarterly net loss alongside commercialization efforts for VIZZ, its FDA-approved presbyopia eye drop, while drawing high short interest and speculative analyst interest.